PRINCETON, N.J., Jan. 25, 2011 /PRNewswire/ — Angelini
Labopharm, LLC, today confirmed Mary Anne Heino’s appointment as
President of the Company. Formerly Senior Vice President,
Sales and Marketing for Labopharm Inc. and President of the
company’s wholly owned subsidiary, Labopharm USA, Inc., Ms. Heino’s
primary focus will be to leverage the Angelini Labopharm joint
venture for the commercialization of OLEPTRO™, as well as to
explore opportunities for line-extensions and the introduction of
other products to the U.S. market through the joint venture.
The Angelini Labopharm joint venture was formed in 2010 for the
U.S. commercialization of OLEPTRO™, a novel, once-daily
formulation of the antidepressant trazodone hydrochloride approved
by the U.S. Food and Drug Administration (FDA) for the symptomatic
relief of major depressive disorder (MDD) in adults.
“As acting President of Angelini Labopharm, Mary Anne played an
instrumental role in the commercial preparation for the U.S. launch
of OLEPTRO™ last August and we look forward to her continued
contributions toward the build out of the joint venture,” said
James R. Howard-Tripp, President and Chief Executive Officer,
Labopharm Inc.
“Mary Anne’s proven leadership in the management of the Angelini
Labopharm joint venture gives us great confidence in the successful
growth and performance of this partnership as we focus on expansion
efforts in the United States,” said Gianluigi Frozzi, Chief
Executive Officer of the Pharmaceutical Division, Gruppo
Angelini.
Prior to joining Labopharm in February 2007, Ms. Heino held
executive positions with Centocor, Inc., a subsidiary of Johnson
& Johnson, including Vice President of Strategic Planning and
Competitive Intelligence and Vice President of Sales, in which she
directed a sales team that generated revenue of more than $2
billion annually. Prior to Centocor, Ms. Heino held a series of
increasingly senior sa
‘/>”/>
